Combination of &ldquo;low-dose&rdquo; ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy

doi:10.3748/wjg.v7.i2.222

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2034)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series.

Item

Count

PDF

207

HTML

1615

Figures (1-3)

212

Sum=2034

Apr 15, 2001 (publication date) through Jul 3, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Articles

World J Gastroenterol. Apr 15, 2001; 7(2): 222-227
Published online Apr 15, 2001. doi: 10.3748/wjg.v7.i2.222

Full Size Figure Download Figure

Figure 2 Outcome of 13 HCV-infected relapsers to IFN monotherapy, including response to combined therapy with IFN and “low-dose” ribivirin for 6 months, response to followed IFN monotherapy for 6 months for complete responders to combined therapy and outcome during follow-up after end of 12 months treatment.

Citation: Wietzke-Braun P, Meier V, Braun F, Ramadori G. Combination of “low-dose” ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol 2001; 7(2): 222-227
URL: https://www.wjgnet.com/1007-9327/full/v7/i2/222.htm
DOI: https://dx.doi.org/10.3748/wjg.v7.i2.222